In early 2014, the Company will launch a trial to test anti-aging properties of its topical cream delivered offering.

LifeApps has won acclaim for its digital offerings and via its recent acquisition of Sports One and the introduction of the Golf Core Grip System, management is gaining real sales traction

In the near term, the pending 3Q13 financial report from Celgene (NASDAQ - CELG), which is due later this week, will place further attention on the pancreatic cancer treatment sector, and by association, Nuvilex. 

Currently, there are only 3 drugs approved for treatment of the disease. But, there are some catalysts up ahead which could drive this group of small cap biotech stocks meaningfully higher.

Management has made another huge step in broadening its reach and diversifying its revenue opportunities.

The fourth quarter of the year is typically a good one for micro cap stocks due to seasonal and macro issues and this year should be no different. For Nuvilex, Inc. (OTCQB – NVLX - $0.12 – Spec Buy) shareholders, the last 3 months of the year should be extra sweet.

Since our coverage initiation in early May 2013, RealBiz (RBIZ- OTCQB - $4.00) has been on a phenomenal tear, achieving major milestones. On the heels of new contracts, the stock has more than doubled during this time to a new year high, busting through our price target and prompting us to substantially raise our price target to $7.00 from $4.00.

Less than a month removed from acquiring rights to a cutting edge nano and micro particle entrapment technology, Plandaí Biotechnology, Inc. (OTCQB – PLPL) has already secured a lucrative out-licensing agreement that could be worth millions in revenue over the next 5 years.

For investors seeking a well-positioned mid-late stage biotechnology company, one may not need to go any further than Nuvilex, Inc. (OTCQB – NVLX - $0.135 – Spec Buy). The Company has nearly all of the characteristics biotech and micro cap investors find attractive and actively seek.